Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
63 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
VIFOR PHARMA BELGIE from Antwerpen, company number BE0829421759, closed financial year 2025 with a result of € 391,451 after tax. For that financial year VIFOR PHARMA BELGIE recorded revenue of € 12.4 million and equity of € 4.3 million. Compared with financial year 2024, the result moved from € 483,438 to € 391,451. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on December 18, 2025.
€ 4.3 million
▲ 10% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 391,451
▼ 19% vs 2024
Profit after tax over the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 4.2 million.
People and assets in 2025
11.2
▲ 1.8 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.6 million
▲ 14% vs 2024
€ 144,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1.6 million
▼ 9% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 53 days on average.
€ 794,948
▲ 83% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 19,629,552 | € 28,553,005 | € 12,487,680 | € 12,367,451 | ▼ 1% |
| Profit after taxes | € 366,548 | € 857,804 | € 483,438 | € 391,451 | ▼ 19% |
| Equity | € 2,533,572 | € 3,391,376 | € 3,874,814 | € 4,266,265 | ▲ 10% |
| Total debts | € 8,553,294 | € 4,688,202 | € 4,113,577 | € 3,670,619 | ▼ 11% |
| Retained profit | € 2,472,072 | € 3,329,876 | € 3,813,314 | € 4,204,765 | ▲ 10% |
| Balance sheet total | € 11,086,866 | € 8,079,578 | € 7,988,392 | € 7,936,884 | ▼ 1% |
| Employees (FTE) | 17.2 | 14.8 | 9.4 | 11.2 | ▲ 1.8 |
Key figures of VIFOR PHARMA BELGIE, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.
What happened to VIFOR PHARMA BELGIE?
What happened at VIFOR PHARMA BELGIE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Theo Nieuwenhuis stepped down as director. NBB
- Alexandros Sigalas stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 391,451 (▼ 19% vs 2024). Source: NBB ↗
- Theo Nieuwenhuis became a director. NBB
- Alexandros Sigalas became a director. NBB
- New establishment in Antwerpen. KBO
- Start of the company according to the CBE. KBO
In short
From € 366,548 profit in 2021 to € 391,451 profit in 2025.
Paid € 982,147 in corporate taxes since 2021.
Best year ever: 2023, with € 857,804 profit.
Pays suppliers within 53 days on average.
A new publication or filing at VIFOR PHARMA BELGIE? We notify you, reason included.
Follow VIFOR PHARMA BELGIEDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Vifor Pharma Participations AG (100%).
Directors
According to the 2025 annual accounts
since 2023 · until 2026
Alexandros Sigalas
Director
since 2023 · until 2026
Shareholders
Vifor Pharma Participations AG
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Uitbreidingstraat 84
2600 Antwerpen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 63 companies are registered at this address.
All companies at this address →Janson Bridging Belgium
€ 396,441 gross margin · 2025
BOLIDT BELGIE
€ 99,680 gross margin · 2025
GraydonCreditsafe Belgium
€ 20.2 million revenue · 2025
A.T.P. Services
€ 336,791 gross margin · 2025
SONNEVELD
€ 650,930 gross margin · 2025
+58 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0829.421.759
- VAT number
- BE 0829.421.759
- Registered office
- Uitbreidingstraat 84, 2600 Antwerpen
- Names & denominations
- VIFOR PHARMA BELGIE
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 21 September 2010
- Peppol
- Active · Active since 25 Jun 2026
- Activities · NACE
Groothandel in farmaceutische en medische artikelen